What is M1T?
M1T (17a-Methyl-1-Testosterone) is an extremely potent oral, 17a-alkylated steroid. It delivers fast, marked gains but comes with a harsh side effect profile - especially strong lethargy, poor well-being and high liver load. Many find the trade-off unfavorable.
This information is for research and educational purposes only. No medical advice.
Comparison
M1T and relatives
Related steroids at the androgen receptor, as described in the TPD lexicon. Tap a card to open its entry.
Simplified: M1T is 1-testosterone with a methyl group at position 17. With this group it also worked orally in animal tests and the authors see a possible liver risk in it. 1210
How it works
M1T activates the androgen receptor very strongly and does not aromatize. The high potency per mg makes it effective, but the central nervous side effects (lethargy, loss of appetite, malaise) and liver load are pronounced.
Where it acts
Where M1T acted in experiments
Tap a point or a card. Prostate, muscle and liver from rat studies, kidneys from a human case report.
- Prostate (rat)
Grew with the amount injected under the skin, more cell division after swallowing1
AR - Muscle (rat)
Levator ani muscle grew after injection, taken by mouth IGF-1 and androgen receptor changed in the calf muscle1
AR - Liver (rat)
Strong effect on a liver enzyme, much stronger after swallowing1
Observed in trials - Kidneys (case report)
Acute kidney injury on M1T alongside ciclosporin, normal within one week after stopping3
Observed in trials
Known targets1
Compound PubChem CID 7092657: one described target, Strong activator in a yeast cell assay.
- Gene
- AR
- UniProt
- P10275
- ChEMBL
- CHEMBL1871
- Action
- Strong activator in a yeast cell assay
Use and dosing
Dosing
Dosing, titration and syringe
Loading the dosing information …
- Getting started and stepping up, drawn as a staircase
- Units on the U-100 syringe for every step
- How long one vial lasts
What the research shows
As a designer/prohormone steroid there are hardly any controlled human studies. The AAS pharmacology (Kicman 2008, Hartgens & Kuipers 2004) classes the properties.
Study results
What the trials measured
Interactive: switch tabs, tap points, show or hide arms. Arms are named relative to each other, no dosing advice.
Kidney and bile marker in the case report3
One patient, values in µmol/l before M1T and on M1T alongside ciclosporin
Single case, not a trial. The liver marker ALT rose from 31 to 304 U/l. After stopping M1T and ciclosporin kidney and liver values were normal within one week. The authors suspect that M1T slowed the breakdown of ciclosporin in the liver.
How little M1T shows up in urine4
Limits of a 2010 lab method in ng/ml of urine, smaller means more sensitive
The method found M1T in a new oral product and identified positive urine samples. According to the paper M1T had been on the prohibited list since 2006.
Research status
Where the research stands
M1T has never been tested in a registered human trial. Doping laboratories have only studied what appears in urine after intake. As of 26 Oct 2026. 9
- Preclinical Yeast cell assay and rats (Hershberger assay)
- Phase 1 no registered trial
- Phase 2 no registered trial
- Phase 3 no registered trial
- Approval not yet
So far there is no registered trial in humans. 9
Side effects
- Lethargy: pronounced - the main problem for many users.
- Liver: 17a-alkylated, very strong - short cycles, liver support.
- Lipids and blood pressure unfavorable.
- HPTA suppression - PCT topic.
Storage
Store dry and cool, protected from light. Out of reach of children.